David A. Siegel Acumen Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 426,300 shares of ABOS stock, worth $758,814. This represents 0.0% of its overall portfolio holdings.
Number of Shares
426,300
Previous 463,700
8.07%
Holding current value
$758,814
Previous $510,000
3.14%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ABOS
# of Institutions
72Shares Held
38.8MCall Options Held
31.5KPut Options Held
0-
Ra Capital Management, L.P. Boston, MA14.9MShares$26.6 Million0.38% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$6.08 Million1.28% of portfolio
-
Franklin Resources Inc San Mateo, CA3.08MShares$5.48 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.84 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.95MShares$3.47 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $72.1M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...